|
|
|
| home > ebr > Spring 2017 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
Editor’s Letter
Dr Deborah O’Neil, Editor of EBR, highlights the connections and debates that interlink the articles by our contributors this issue, with a particular focus on the protein problem and the need for tighter regulation across fields such as biomarkers and personalised medicine.
|
|
|
|
Biological Complexity & Drug Discovery
A Complex System
When considering the cell as a complex system it is possible to uncover new opportunities in drug discovery, says Jonny Wray at e-Therapeutics – and their applications are wide-ranging and certainly beneficial.
|
|
|
Identifying the Need for New Drugs
Opening Doors
Benoît Laleu, Jaya Banerji and Paul A Willis at Medicines for Malaria Venture discuss the Malaria and Pathogen Boxes, which emphasise the importance and benefits of collaboration and open source approaches in drug discovery.
|
|
|
|
In Brief
Just Value
Emile Bellott, EBR’s Industry Advisor, investigates how to successfully create a supply-side business model taking into account value in negotiating with manufacturers on drug prices.
|
|
|
CDMO Developments
Seize the Market
Rentschler Biotechnologie’s Dr Stefan R Schmidt and Dr Birgit Schwab investigate how mid-size contract development and manufacturing organisations can take advantage of the biopharmaceutical market. Updating their facilities and researching personalised medicines, they argue, could be the answer.
|
|
|
|
Spotlight
Managing E&L Unknown Compounds
With unknown compound characterisation representing a challenging aspect of analytical chemistry, Eurofins BioPharma Product Testing investigates extractables and leachables as well as the importance of knowing your compounds.
|
|
|
|
Cells and Serums
Culture Clash
Jessie HT Ni at Irvine Scientific explores the latest developments in the world of serums. With their benefits and risks well known, we are beginning to further understand their effects on phenotypes and, as a result, our knowledge of cell biology is expanding.
|
|
|
Q&A: Genetic Modification
Express Yourself
We learn about the possibilities of cell engineering, genetic modification and protein production in this Q&A feature with the team at Oxford Genetics, who say that it could be possible to cure inherited diseases with new technology.
|
|
|
|
Protein Identification
Becoming Better Informed
Christian Loch at AVMBioMed suggests that proteomics may be the best tool for characterising investigational molecules and identifying useful biomarkers. However, this needs to be done more reproducibly and should account for post-translational modification.
|
|
|
Biomarkers and Personalised Medicine
Essential Tools
Dr Mélanie Bodnar-Wachtel and Dr Tanja Schubert at Bioclinica Lab reveal how biomarkers are being used in the treatment of Alzheimer’s disease and cancer. As they become essential, they are revolutionising the manufacture of advanced therapies and allowing for new and innovative practices and partnership.
|
|
|
Therapeutic Transportation
Stay Cool
When transporting manufactured drugs, there are many factors that have the potential to damage product integrity. John Fink and Katheryn Shea at Brooks Life Science Systems explore best practices to avoid this with regards to cryopreservation.
|
|
|
Protein Production
Balancing Act
Cytovance’s April Stanley explores different approaches for successful therapeutic protein production. The most effective ones, she argues, involve both integration and partnership.
|
|
|
Patient Stratification
Personalised Immuno-Oncology
As global cancer diagnoses are set to surge, the implementation of biomarkers like autoantibodies could be a saving grace for the development of effective immunotherapies in the field of oncology, argue Dr Peter Schulz-Knappe and Dr Georg Lautscham at Protagen.
|
|
|
Q&A: Biomarkers in Oncology
Pinpointing the Problem
ICON Laboratories’ Dr Mario L Rocci Jr shares his insights on the use of biomarkers in oncology with particular focus on PD-L1 and tumour-infiltrating lymphocytes.
|
|
|
Influenza Viruses
Going Viral
Human challenge trials could lead the way in real world validation of medication efficacy, believes Adrian Wildfire at SGS Life Sciences. He states that various strains of the influenza virus are acceptable candidates for such studies, and explains some of the reasons why they are so effective.
|
|
|
Peptides and Proteomics
Perfecting Progress
Although proteomics lacks sufficient global legislative procedures, Kim Plasman, Kris Gevaert, Francis Impens and Tony Montoye put forward several methods for improving the quality of workflows through accurate peptide quantification.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Datwyler patents sustainable cellulose-based fillers
October 25, 2022 - Datwyler, together with the development partner Empa, has developed and patented an industrial process for surface modification of microfibrillated cellulose (MFC). The modified MFC can be used to substitute petroleum-based aramid fibers as fillers in elastomer compounds. Fillers derived from organic cellulose increase the sustainability of elastomer products.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trials in Emerging Markets: Goldmines or Landmines?
Pharm-Olam, LLC
Over the past decade, biopharmaceutical companies
have increasingly turned to emerging markets as a way
to reduce clinical trial costs and timelines. Areas such
as Eastern Europe, India, and Latin America—with their
ready population of treatment naïve patients—can be an
answer to the intense competition for patients seen in
developed markets. Many of the countries within these
regions may now be considered as “emerged” countries
but yet, conducting trials in these regions does require
some special attention and expertise. Before deciding to
conduct studies in these areas, companies should have a
full appreciation for the ethical, medical, regulatory, legal,
and operational hurdles that must be surmounted for
success. Here we highlight a number of those issues and
offer our recommendations for how sponsor companies
can deal with them effectively.
More info >> |
|
|
